Aptus Capital Advisors LLC Sells 30,044 Shares of Stryker Corporation $SYK

Aptus Capital Advisors LLC reduced its position in shares of Stryker Corporation (NYSE:SYK) by 26.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 82,692 shares of the medical technology company’s stock after selling 30,044 shares during the quarter. Aptus Capital Advisors LLC’s holdings in Stryker were worth $29,064,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of SYK. Godfrey Financial Associates Inc. bought a new stake in shares of Stryker in the fourth quarter worth approximately $26,000. United Financial Planning Group LLC bought a new stake in shares of Stryker in the third quarter worth approximately $27,000. DJE Kapital AG bought a new stake in shares of Stryker in the fourth quarter worth approximately $28,000. Strive Asset Management LLC bought a new stake in shares of Stryker in the third quarter worth approximately $30,000. Finally, CGC Financial Services LLC bought a new stake in shares of Stryker in the fourth quarter worth approximately $29,000. 77.09% of the stock is currently owned by institutional investors.

Insider Transactions at Stryker

In other news, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the transaction, the vice president owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the business’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the transaction, the director directly owned 1,924,880 shares in the company, valued at $601,005,282.40. This trade represents a 13.87% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 323,264 shares of company stock valued at $100,659,489. 4.60% of the stock is currently owned by corporate insiders.

Stryker Stock Performance

Shares of NYSE SYK opened at $312.14 on Friday. The firm has a 50 day moving average of $316.40 and a 200 day moving average of $343.97. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $119.66 billion, a price-to-earnings ratio of 36.13, a price-to-earnings-growth ratio of 1.97 and a beta of 0.78. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $404.87.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. During the same quarter last year, the firm posted $2.84 earnings per share. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, research analysts anticipate that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s payout ratio is 40.74%.

Analysts Set New Price Targets

A number of analysts have recently commented on SYK shares. Canaccord Genuity Group reduced their price target on shares of Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a research note on Friday, May 1st. UBS Group reduced their price target on shares of Stryker from $400.00 to $380.00 and set a “neutral” rating for the company in a research note on Tuesday, March 17th. Citigroup reduced their price target on shares of Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a research note on Tuesday, April 7th. Deutsche Bank Aktiengesellschaft set a $315.00 price target on shares of Stryker in a research note on Friday, May 1st. Finally, Robert W. Baird set a $385.00 price target on shares of Stryker in a research note on Friday, May 1st. Sixteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $395.33.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.